December 15, 2017 / 12:06 PM / 9 months ago

BRIEF-Pharma Mar Says CHMP Against Approving MAA Of Aplidin For Multiple Myeloma Treatment

Dec 15 (Reuters) - PHARMA MAR SA:

* THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ISSUES OPINION AGAINST APPROVAL OF THE MARKETING AUTHORIZATION APPLICATION (MAA) OF APLIDIN FOR TREATMENT OF RELAPSED MULTIPLE MYELOMA

* AFTER OPINION OF CHMP, EUROPEAN COMMISSION TO ISSUE FINAL DECISION, EXPECTED IN MARCH OR APRIL, 2018 Source text for Eikon:

Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below